Drug Profile
Research programme: lung transplant rejection therapies - Vectura
Alternative Names: VR-909Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Vectura
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes
Highest Development Phases
- No development reported Lung transplant rejection
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Lung-transplant-rejection in England
- 07 Jul 2011 Research programme is available for licensing as of 07 Jul 2011. http://www.vectura.com/products/
- 07 Jul 2011 Preclinical trials in Lung transplant rejection in USA (unspecified route)